Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist peptide. Preclinical and clinical research has examined its simultaneous binding kinetics at GIP and GLP-1 receptors, downstream intracellular cAMP signaling cascades, and pancreatic beta-cell receptor activation profiles in controlled in vitro and animal model systems. Published literature has also characterized its pharmacokinetic parameters including half-life, subcutaneous bioavailability, and receptor binding affinity ratios under research conditions.
\n
Class: Dual GIP/GLP-1 Receptor Agonist | Purity: ≥98% (HPLC) | Format: Lyophilized powder
\n
Storage: −20°C, desiccated, protected from light | Reconstitution: Bacteriostatic water recommended for research use
\n
\n
⚠️ Research Use Only. This compound is intended exclusively for qualified in vitro and laboratory research. It is not approved for human consumption, is not a dietary supplement, and has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease or health condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws governing research chemical use.
